RT Journal
A1 Nissen SE
T1 CYp2c19 genotype and cardiovascular events—reply
JF JAMA
JO JAMA
YR 2012
FD April 11
VO 307
IS 14
SP 1482
OP 1485
DO 10.1001/jama.2012.447
UL http://dx.doi.org/10.1001/jama.2012.447
AB 
I could not more strongly disagree. For decades, women were treated with hormone therapy to prevent heart disease based on observational studies, only to find out that such treatments increase, rather than decrease, morbidity and mortality.1- 2 Similarly, inappropriate use of surrogate end points has repeatedly promoted adoption of therapies that later proved ineffective or harmful. Examples include drugs to increase high-density lipoprotein cholesterol or reduce blood glucose such as rosiglitazone.3- 4 Platelet reactivity testing represents another unvalidated surrogate end point and cannot be a substitute for studies that measure morbidity and mortality, which are the outcomes of importance to patients and physicians.